Oncology & Cancer

Researchers find new pathway underlying multiple myeloma relapse

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved ...

Oncology & Cancer

Empliciti approved for multiple myeloma

(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...

Oncology & Cancer

Rates of kidney failure due to blood cancer are declining

The risk of kidney failure caused by multiple myeloma appears to be declining, and survival is lengthening for patients who do develop kidney failure due to this cancer. The findings, which are published in a study appearing ...

page 7 from 19